Physician profile
Maranda Streit
NPI 1649832072
$12,183.36
in general payments reported to CMS, 2019-2025
34 companies · $2,663 in 2025
The $2,663 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,102 · 2022: $1,967 · 2023: $2,582 · 2024: $1,870 · 2025: $2,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,114.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,283.51 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,263.69 | 2021-2025 | Jardiance, Ofev, Stiolto Respimat |
| Glaxosmithkline, LLC. | $1,392.80 | 2021-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Novo Nordisk INC | $732.85 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $626.66 | 2021-2025 | |
| Lilly USA, LLC | $595.61 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Mylan Specialty L.P. | $526.67 | 2021-2024 | Yupelri |
| Amgen INC. | $395.69 | 2021-2025 | Evenity, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $360.43 | 2021-2024 | Xarelto |
| Paratek Pharmaceuticals, INC. | $302.45 | 2021-2025 | Nuzyra |
| Verona Pharma, INC. | $213.42 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.35 | 2023-2024 | Xifaxan |
| Amarin Pharma, INC. | $179.00 | 2021 | |
| Abbott Laboratories | $127.23 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Grifols USA, LLC | $120.91 | 2021-2025 | Prolastin-C Liquid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $118.11 | 2021-2025 | Dupixent |
| Viatris Specialty LLC | $104.96 | 2025 | Yupelri |
| Exact Sciences Corporation | $83.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Insmed, INC. | $75.87 | 2024-2025 | Arikayce, Brinsupri |
| Esperion Therapeutics, INC. | $63.85 | 2024-2025 | Nexletol |
| Pfizer INC. | $55.53 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $40.76 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $38.88 | 2021 | |
| Merck Sharp & Dohme LLC | $38.25 | 2021-2025 | Gardasil 9, Capvaxive |
| Viiv Healthcare Company | $32.09 | 2024 | Apretude |
| Saluda Medical Americas, INC. | $29.46 | 2025 | Evoke |
| Biohaven Pharmaceutical Holding Company LTD. | $29.43 | 2022 | |
| Optinose US, INC. | $26.91 | 2025 | |
| Baxter Healthcare | $26.89 | 2022 | |
| Gilead Sciences, INC. | $26.21 | 2025 | |
| Abbvie INC. | $17.29 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $16.17 | 2021 | |
| Cashflow Solutions, LLC | $13.65 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Genzyme Corporation | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maranda Streit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.